Good news, for Kenilworth, and cancer patients. The high burden disease states await. Here's the Merck presser:
. . . .[Merck] today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating Keytruda® (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the study’s independent Data Monitoring Committee. . . .
Enjoy a productive Tuesday now, one and all.
No comments:
Post a Comment